ROSTOCK, Germany--(BUSINESS WIRE)--Jun 5, 2018--CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate treatments for rare diseases, today announced the opening of its first U.S.-based rare disease laboratory in Cambridge, Massachusetts. The new facility, opening on August 1, 2018, will be the central point of contact for CENTOGENE’s collaboration partners that leverage its diagnostic services in the U.S.

The new office space will feature a state-of-the-art high-throughput genetic testing laboratory along with biochemical, proteomic, metabolomic and genetic analysis capabilities from various patient sample materials, such as CentoCard®, CENTOGENE’s dried blood spot card (DBS) solution, buccal swab, full blood or purified DNA.

“CENTOGENE is one hundred percent focused on translating rare disease genetics into medical breakthroughs and we are thrilled to continue our global expansion into the preeminent biotech hub of Cambridge,” said Dr. Arndt Rolfs, CEO and founder of CENTOGENE. “As a company that is at the nexus of elucidating rare hereditary diseases by combining proteomic, metabolomics and genomic solutions, we look forward to working even more closely with our pharmaceutical, academic and medical partners in the U.S.”

An estimated 350 million people worldwide suffer from rare diseases, with 30 percent not living to see their fifth birthday. With a diagnosis often taking more than 8 years, there is tremendous unmet need in early diagnosis and treatment options. With the patient at the heart of CENTOGENE’s mission, the company provides solutions that target early diagnostics and support for pharmaceutical companies to help identify and accelerate treatments. Its biomarker technology clearly supports measuring the effectiveness of treatment and is supportive in the development toward more personalized medicines.

About CENTOGENE

CENTOGENE unlocks the power of genetic insights to improve the quality of life of patients with rare genetic diseases. We achieve this through knowledge, created by our worldwide diagnostic testing services, incorporating global diversity, the world’s leading proprietary human genetic interpretation database, CentoMD® and solutions for pharmaceutical companies developing life-changing orphan drugs.

As the most diversified and largest genetic testing companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients and their families. www.centogene.com; www.centoMD.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20180604006511/en/

CONTACT: Centogene:

Ruxandra Lenz, +49 30 213 000 323

Director Communications

Ruxandra.Lenz@centogene.com

or

Media Contact:

MacDougall Biomedical Communications

Lauren Arnold, +1 781-235-3060

larnold@macbiocom.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MASSACHUSETTS GERMANY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL OTHER HEALTH GENERAL HEALTH MANAGED CARE

SOURCE: CENTOGENE

Copyright Business Wire 2018.

PUB: 06/05/2018 02:00 AM/DISC: 06/05/2018 02:01 AM

http://www.businesswire.com/news/home/20180604006511/en